甘精胰岛素对2型糖尿病患者血浆胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-1和血管内皮细胞生长因子的影响

Effect of insulin glargine on plasma FIGF-1,IGFBP-1 and VEGF in patients with type 2 diabetes

目的探讨甘精胰岛素对T2DM患者血浆游离胰岛素样生长因子-1(FIGF-1)、胰岛素样生长因子结合蛋白-1(IGFBP-1)、血管内皮细胞生长因子(VEGF)的影响。方法将患者随机分为甘精胰岛素治疗组和中性胰岛素(NPH)治疗组,比较两组在治疗0,3,6,12个月时血浆HbA1c、FIGF-1、IGFBP-1、VEGF浓度及治疗期间发生低血糖次数。结果甘精胰岛素治疗组HbA1c、VEGF在治疗后6、12个月与NPH治疗组差异均有统计学意义(P均<0.05);IGFBP-1在治疗后3、6、12个月明显低于NPH治疗组(P<0.05);两组FIGF-1差异均无统计学意义(P>0.05);两组低血糖发生次数差异有统计学意义(P<0.05)。结论与NPH比较,甘精胰岛素能更好地控制血糖,增加患者血浆VEGF,降低IGFBP-1,对FIGF-1无影响。

Objective To explore the effect of insulin glargine on the plasma free insulin-like growth factor-1(FIGF-1),insulin-like growth factor binding protein-1(IGFBP-1),and vascular epithelium growth factor(VEGF) in T2DM patients.Methods The patients were randomized into two groups,one group was treated with neutral protamine hagedom's insulin(NPH) and the other treated with glargine insulin(Glargine).The plasma concentration of HbA1c,IFGF-1,IGFBP-1,and VEGF in the 0,3rd,6th,and 12th month of treatment,and the frequency of hypoglycemia were compared between the two groups.Results HbA1c and VEGF were lower in the glargine group than in the NPH group in 6th and 12th month(P<0.05),IGFBP-1 was significantly lower in than glargine in the NPH group in 3rd,6th,and 12th month(P<0.05).The difference in FIGF-1 between the two groups was not significant in statistics(P>0.05).The difference of incidence of hypoglycemia was significant in statistics between the two groups(P<0.05).Conclusion Compared with NPH,insulin glargine has a better effectiveness on blood glucose control,increase of plasma VEGF,and decrease of IGFBP-1,without effect on FIGF-1.